Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus
darolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),
the six-month radiographic progression free survival (“rPFS”) rate was 66%